The PROphet® report shows a prediction of the patient’s clinical benefit (progression-free survival >12 months) from PD-1/PD-L1 inhibitor immunotherapy-based treatment plans.
Combining these findings with a patient’s PD-L1 level allows for a clear distinction between those who will benefit from immunotherapy alone versus immunotherapy combined with chemotherapy. This may improve the patient’s overall response rate.
PROphet® thereby addresses one of the most common daily dilemmas of the oncologist with an accuracy and level of resolution that simply does not exist today.
The PROphetNSCLC™ test optimizes first-line immunotherapy treatment outcomes for advanced, unresectable non-small cell lung cancer patients, predicting clinical benefit probability (at least 12 months of progression-free survival) in response to PD-1/PD-L1 inhibitors - as a single agent or in combination with chemotherapy.
The PROphet platform combines bioinformatics, system biology, proteomic pattern recognition and machine learning in a cancer patient’s blood plasma to analyze and identify proteomic profiles.
PROphetNSCLC™ provides clinicians with actionable clinical insights into optimal first-line therapeutic choices, and a better understanding of their patient's personalized cancer dynamics.
PROphetNSCLC™ is intended for use as a decision support tool, providing additional information to the physician in the management of newly-diagnosed stage IV non-small cell lung cancer (NSCLC) patients.
The PROphet® model was developed on blood samples and clinical data collected from a cohort of 625 patients treated with PD-1/PD-L1 inhibitors taking part in OncoHost’s ongoing, international, multicenter clinical trial (PROPHETIC; NCT04056247).
As a comparator for PD-L1<1% and PD-L1 1-49%, PROphet® predictions were compared to a retrospective cohort of 85 patients treated with chemotherapy.
Patient clinical data were recorded, including demographics, clinical characteristics, and clinical benefit. Blood plasma was profiled by the SomaScan® Discovery Assay v4.1, and the resulting proteomic profiles were analyzed in conjunction with patient clinical data. Specifically, a proprietary prediction algorithm was developed to identify proteomic patterns associated with clinical benefit in response to PD-1/PD-L1 inhibitors.
To date, we do not have a very effective way of predicting response to therapy for these patients. PROphet®️ is an answer to that dilemma. It️ helps me understand just how much therapy I need in my patients with advanced NSCLC and reassures me in my decision-making.
Dr. Jason Porter
PROphet®️ helps guide my treatment decisions by predicting patient response and better understanding how the treatment will work. The test is easy to obtain and reliable.
Dr. Venkat Pavan Kancharla
PROphet®️ is a new technology that allows us to see who will have significant benefit from IO alone, therefore potentially avoiding the need for chemo and over-treating patients.
Dr. Sam Huang
I had a few patients who had high PD-L1, with no response to single-agent Pembro treatment, and with rapidly progressive disease. PROphet®️ has been very helpful in this setting.
Dr. Geeta Kurra
PROphet®️ in my opinion is not only predictive but also prognostic. What stands out about the test is its strong validation process and being quick and easy to obtain.
Dr. Edgardo Santos
To date, we do not have a very effective way of predicting response to therapy for these patients. PROphet®️ is an answer to that dilemma. It️ helps me understand just how much therapy I need in my patients with advanced NSCLC and reassures me in my decision-making.
Dr. Jason Porter
PROphet®️ helps guide my treatment decisions by predicting patient response and better understanding how the treatment will work. The test is easy to obtain and reliable.
Dr. Venkat Pavan Kancharla
PROphet®️ is a new technology that allows us to see who will have significant benefit from IO alone, therefore potentially avoiding the need for chemo and over-treating patients.
Dr. Sam Huang
I had a few patients who had high PD-L1, with no response to single-agent Pembro treatment, and with rapidly progressive disease. PROphet®️ has been very helpful in this setting.
Dr. Geeta Kurra
PROphet®️ in my opinion is not only predictive but also prognostic. What stands out about the test is its strong validation process and being quick and easy to obtain.
Dr. Edgardo Santos
On March 7, 2023, we partnered with the International Society of Liquid Biopsy (ISLB) to discuss unmet needs in predictive immuno-oncology biomarkers.
Prof. David Gandara, MD – The Unmet Need for Predictive Biomarkers of Immunotherapy
Dr. Ofer Sharon - PROphet®: A Plasma Proteomic Predictive Biomarker for Immunotherapy
Prof. David Carbone - PROphet®: Validation & Clinical Utility
Our lab uses high-throughput protein analysis technology to quantify the levels of thousands of proteins in a single plasma sample. The proteins include cytokines, chemokines, growth factors, and enzymes associated with therapy resistance and tumor spread.
The lab is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). The PROphetNSCLC™ test is intended for clinical purposes.
*CLIA number: 34D2250951
Please fill in the form below and the relevant OncoHost contact will be in touch with you soon!
A relevant contact will be in touch soon
